MétaCan
Menu
Back to cohort
Record W2460121490 · doi:10.18632/oncotarget.10308

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

2016· article· en· W2460121490 on OpenAlexaffabout
Hubert Fleury, Eurı́dice Carmona, Vincent Morin, Liliane Meunier, Jean‐Yves Masson, Patricia N. Tonin, Diane Provencher, Anne‐Marie Mes‐Masson

Bibliographic record

VenueOncotarget · 2016
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsGenome CanadaMcGill University Health CentreUniversité de MontréalUniversité LavalMcGill UniversityCentre Hospitalier de l’Université de Montréal
Fundersnot available
KeywordsPARP inhibitorSerous ovarian cancerPoly ADP ribose polymeraseCancer researchOvarian cancerDNA damageSerous fluidEpithelial ovarian cancerDNA repairMedicineOlaparibCancerBiologyOncologyDNAInternal medicineGeneticsPolymerase

Abstract

fetched live from OpenAlex

// Hubert Fleury 1, 2 , Euridice Carmona 1, 2 , Vincent G. Morin 1, 2 , Liliane Meunier 1, 2 , Jean-Yves Masson 3, 4 , Patricia N. Tonin 5, 6, 7 , Diane Provencher 1, 2, 8 and Anne-Marie Mes-Masson 1, 2, 9 1 Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Canada 2 Institut du cancer de Montréal, Montreal, Canada 3 Genome Stability Laboratory, CHU Research Center, Québec City, Canada 4 Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, Canada 5 Cancer Research Program (CRP), The Research Institute of the McGill University Health Centre, Montreal, Canada 6 Department of Human Genetics, McGill University, Montreal, Canada 7 Department of Medicine, McGill University, Montreal, Canada 8 Division of Gynecologic Oncology, Université de Montréal, Montreal, Canada 9 Department of Medicine, Université de Montréal, Montreal, Canada Correspondence to: Anne-Marie Mes-Masson, email: anne-marie.mes-masson@umontreal.ca Keywords: olaparib, high-grade serous epithelial ovarian cancer, DNA repair pathways, NER, MMR Received: January 27, 2016     Accepted: June 09, 2016     Published: June 27, 2016 ABSTRACT PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly associated with homologous recombination (HR) deficiency, but clinical trials have shown that predicting actual patient response is complex. Here, we investigated gene expression microarray, HR functionality and Olaparib sensitivity of 18 different HGS EOC cell lines and demonstrate that PARPi sensitivity is not only associated with HR defects. Gene target validation show that down regulation of genes in the nucleotide excision repair (NER) and mismatch repair (MMR) pathways ( ERCC8 and MLH1 , respectively) increases PARPi response. The highest sensitivity was observed when genes in both the HR and either NER or MMR pathways were concomitantly down regulated. Using clinical samples, patients with these concurrent down regulations could be identified. Based on these results, a novel model to predict PARPi sensitivity is herein proposed. This model implies that the extreme responders identified in clinical trials have deficiencies in HR and either NER or MMR.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.433
Threshold uncertainty score0.816

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.295
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations43
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueOncotargetSame topicPARP inhibition in cancer therapyFrench-language works237,207